Caplin Point Laboratories delivered robust financial performance in Q1 FY27, with consolidated net profit rising 17.5% year-on-year to ₹179.6 crore compared to ₹152 crore in Q1 FY26. The company's basic earnings per share (EPS) grew 15.8% to ₹23.27 from ₹20.10 in the corresponding quarter of the previous year, demonstrating strong operational efficiency and market positioning during the quarter.
The company's total revenue climbed 20% year-on-year to ₹610.3 crore, up from ₹510 crore in Q1 FY26, supported by accelerated contributions from its US operations and steady expansion in Latin America. US market revenue surged 26% to ₹137 crore, emerging as a key growth driver for the quarter. US subsidiary Caplin Steriles US tripled revenue to ₹43.1 crore from ₹14.4 crore a year earlier, demonstrating strong momentum in the regulated market. This significant revenue growth indicates strong demand for the company's products and effective market penetration strategies across multiple geographies.
The company's EBITDA rose 20.1% year-on-year to ₹213.5 crore with EBITDA margin expanding to 38.4% from 37.1% in the previous year, reflecting operational leverage and effective cost management. Profit Before Tax increased 22.1% to ₹225.23 crore, indicating strong operational performance across all profitability metrics. Gross margin held at 59.8%, above the company's long-term target of 55%, while operating expenses as a share of revenue edged down to 23.6% from 23.7%, resulting in improved operational efficiency. The company maintained a robust balance sheet with cash and cash equivalents climbing to ₹1,500 crore and total liquid assets reaching ₹2,875 crore as of June 30, 2026.
Caplin Point Steriles Limited (CSL), the subsidiary responsible for US operations, continues to drive momentum with 60 approved ANDAs and a pipeline of over 40 products under filing or advanced development. CSL has launched 38 products in the US so far, with plans to introduce 12 more in FY27. The company also secured emergency tenders worth $7 million across Central America and $12 million in Chile, reinforcing its presence in Latin America. In leadership developments, the Board approved the re-appointment of Dr. Sridhar Ganesan as Managing Director for two years, effective August 25, 2026, and appointed Mr. D. Muralidharan as Whole-Time Director, effective August 12, 2026.
Management highlighted that current capacity constraints are the main challenge rather than demand, with key plants running near full utilization. The company operates seven sterile injectable lines currently and plans to expand to 17 lines within a year, with Line 7 expected to start in six to seven months. Product transfers from current facilities to new lines will take approximately 9 to 10 months due to regulatory requirements including post-approval supplements and stability testing. The company remains booked out until February 2027, underscoring strong demand but highlighting capacity bottlenecks. Management outlined longer-term initiatives including expansion of US sterile injectable platform, growth in oncology and ophthalmic products, development of API capacity for backward integration, and possible expansion in Mexico and Brazil.
